open access
New aspects of postmenopausal osteoporosis treatment with micronized estradiol and progesterone
open access
Abstract
Objectives: The aim of the study was to assess the effectiveness of postmenopausal osteoporosis treatment with natural sex hormones.
Material and methods: The single-blind study included 210 women, randomly allocated to three different groups, with various methods of treatment: Group I (70 controls) received transcutaneous placebo for the course of one year, Group II (70 females, aged 52.2 ± 3.1 years) used oral hormone supplementary therapy (HST), and Group III (70 females, aged 51.9 ± 3.5 years) received transcutaneous modified hormone replacement therapy (MHRT), supplemented with intravaginal lutein, dietary minerals, and 1000 IU of vitamin D3/day.
Results: No increase in bone mineral density was observed in the control group. However, mineral density of the vertebral bodies was significantly higher after 3 and 5 years in the HST group (p < 0.05), and after 1 year in the MHRT group (p < 0.01). This increase was even more significant (p < 0.001) after 3 and 5 years in the MHRT group.
Conclusions: Transcutaneous hormone therapy with micronized estradiol and progesterone is the treatment of choice in postmenopausal osteoporosis, as evidenced by bone mineral density and biochemical markers.
Abstract
Objectives: The aim of the study was to assess the effectiveness of postmenopausal osteoporosis treatment with natural sex hormones.
Material and methods: The single-blind study included 210 women, randomly allocated to three different groups, with various methods of treatment: Group I (70 controls) received transcutaneous placebo for the course of one year, Group II (70 females, aged 52.2 ± 3.1 years) used oral hormone supplementary therapy (HST), and Group III (70 females, aged 51.9 ± 3.5 years) received transcutaneous modified hormone replacement therapy (MHRT), supplemented with intravaginal lutein, dietary minerals, and 1000 IU of vitamin D3/day.
Results: No increase in bone mineral density was observed in the control group. However, mineral density of the vertebral bodies was significantly higher after 3 and 5 years in the HST group (p < 0.05), and after 1 year in the MHRT group (p < 0.01). This increase was even more significant (p < 0.001) after 3 and 5 years in the MHRT group.
Conclusions: Transcutaneous hormone therapy with micronized estradiol and progesterone is the treatment of choice in postmenopausal osteoporosis, as evidenced by bone mineral density and biochemical markers.
Keywords
postmenopausal osteoporosis; prolactin; estrogens; growth hormone; alkaline phosphatase; mineral density
About this articleTitle
New aspects of postmenopausal osteoporosis treatment with micronized estradiol and progesterone
Journal
Issue
Article type
Research paper
Pages
739-744
Published online
2016-11-30
Page views
2037
Article views/downloads
2232
DOI
10.5603/GP.2016.0080
Pubmed
Bibliographic record
Ginekol Pol 2016;87(11):739-744.
Keywords
postmenopausal osteoporosis
prolactin
estrogens
growth hormone
alkaline phosphatase
mineral density
Authors
Jarosław von Mach-Szczypiński
Stanisław Stanosz
Jakub Kościuszkiewicz
Krzysztof Safranow
